Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Psilocybin for Major Depressive Disorder (MDD)
Sponsor: Usona Institute
Summary
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo. The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 43 post-dose.
Official title: A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)
Key Details
Gender
All
Age Range
21 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
347
Start Date
2020-01-23
Completion Date
2022-06-28
Last Updated
2026-04-22
Healthy Volunteers
No
Conditions
Interventions
Psilocybin
The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
Niacin
The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
Set and Setting (SaS) Protocol
The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
Locations (11)
University of California, San Francisco
San Francisco, California, United States
Pacific Neuroscience Institute
Santa Monica, California, United States
Yale University
New Haven, Connecticut, United States
Segal Trials
Lauderhill, Florida, United States
Emory University
Atlanta, Georgia, United States
Great Lakes Clinical Trials
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Hassman Research Institute
Berlin, New Jersey, United States
New York University School of Medicine
New York, New York, United States
Cedar Clinical Research
Draper, Utah, United States
University of Wisconsin - Madison
Madison, Wisconsin, United States